MHRA与FDA发布抗流感病毒药物的安全性信息
被引量：1
摘要
英国药品和健康产品管理局（MHRA）持续发布的关于抗流感病毒药物奥司他韦（达菲）和扎那米韦（依乐韦）的不良反应分析报告中，收集了2009年4月至2010年1月期间关于这两种在去年甲型H1N1流感中广泛应用的抗流感病毒药物临床不良反应的病例报告，并对其安全性进行了分析总结。报告中指出，两种药均未发现新的安全问题。
出处
《中国危重病急救医学》
CAS
CSCD
北大核心
2010年第2期88-88,共1页
Chinese Critical Care Medicine
同被引文献40
-
1World health organization. State of the art of vaccine research and development [EB/OL]. (2005-01)[2012-02-17].http://www. who.int/vaecine_research/documents/Dip%20814.pdf.
-
2NAIR H, BROOKS WA, KATZ M, et ol. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis[J]. Lancet, 2011, 378(9807) : 1917-1930.
-
3SUGAYA N. Widespread use of neuraminidase inhibitors in Japan[J]. J Infect Chemother, 2011, 17(5): 595-601.
-
4HOIZER CT, von ITZSTEIN M, JIN B, et al. Inhibition of sialidases from viral, bacterial and mammalian sources by analogs of 2 - deoxy - 2,3 - didehydro - N - acetylneuraminie acid modified at the C-4 position[J]. Glycoconj J, 1993, 10(1): 40- 44.
-
5PEGG MS, yon ITZSTEIN M. Slow- binding inhibition of sialidase from influenza virus [J]. Biochem Mol Biol Int, 1994, 32(5): 851-858.
-
6von ITZSTEIN M, WU WY, KOK GB, et al. Rational design of potent sialidase- based inhibitors of influenza virus replication [J]. Nature, 1993, 363(6428) : 418-423.
-
7World health organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses [EB/OL].(2010-02)[2012-02-17]. http://www. who.int/csr/resources/publications/swineflu/hlnl use antivirals _20090820/en/.
-
8HAYDEN FG, OSTERHAUS AD, TREANOR JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections[J]. N Engl J Med, 1997, 337(13) : 874-880.
-
9PUZELLI S, FACCHINI M, di MARTINO A, et al. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic[J]. Antiviral Res, 2011, 90(3): 205-212.
-
10HUANG P, LIANG LJ, HOU NM, et al. Phylogenetic,molecular and drug- sensitivity analysis of HA and NA genes of human H3N2 influenza A viruses in Guangdong, China, 2007-2011[J]. Epidemiol Infect, 2013, 141(5): 1061-1069.
二级引证文献3
-
1董虹,张欢欢,黄晴,曹日昇,周雅,胡一桥.高效液相色谱法测定扎那米韦含量及有关物质[J].中国新药杂志,2018,27(1):31-37. 被引量：1
-
2白辰,刘铁钢,徐竞男,马雪颜,李卓,于河,谷晓红.基于网络药理学的银翘散合桑菊饮加减方、麻杏石甘汤加减方与抗病毒西药作用机制比较——以2018初冬流行性感冒轻症为例[J].中医杂志,2019,60(11):928-934. 被引量：32
-
3成人流行性感冒抗病毒治疗共识专家组,蒋荣猛,金荣华,张文宏,韩冰,王森.成人流行性感冒抗病毒治疗专家共识[J].中华传染病杂志,2022,40(11):641-655. 被引量：4
-
1白加黑、新康泰克等多种感冒药被指不良反应致死[J].世界临床药物,2009,30(4):255-255.
-
2王兰明.制药企业在药品不良反应监测工作中的作用[J].华夏医药,2002,6(3):23-24.
-
3蒋彦章.WHO全球药品不良反应信息(43)[J].药物流行病学杂志,2010,19(9):542-542.
-
4英国建议环孢素必须按商品名称处方和分发[J].中国执业药师,2010(5):17-17.
-
5英国警告口服二膦酸盐的食管癌风险[J].中国执业药师,2011,8(3):19-20.
-
6药物警戒快讯[J].中国药物警戒,2014,11(9):573-576.
-
7刘琛.托莫西汀可致血压升高和心率加快[J].药物不良反应杂志,2012,14(1):14-14.
-
8英国发布他汀类药物的获益/风险分析报告[J].中国药物评价,2014,31(4):253-253.
-
9邵明立局长会见英国药品与健康产品管理局代表团一行[J].中国药事,2008,22(11).
-
10百时美施贵宝公司通知停用依非韦伦100mg胶囊[J].中国执业药师,2009(6):19-20.
